Shopping Cart
- Remove All
- Your shopping cart is currently empty
Azelaoyl PAF is a potent PPARγ agonist that competitively binds thiazolidinediones with potency comparable to rosiglitazone. In atherosclerosis studies, Azelaoyl PAF promotes the uptake of oxidized low-density lipoprotein (oxLDL) by macrophages by upregulating CD36 expression. In fibroblasts from Friedreich's ataxia (FRDA) patients, Azelaoyl PAF significantly increased mRNA and protein levels of ferritin.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
500 μg | Inquiry | 35 days | |
1 mg | Inquiry | 35 days | |
5 mg | Inquiry | 35 days | |
10 mg | Inquiry | 35 days |
Description | Azelaoyl PAF is a potent PPARγ agonist that competitively binds thiazolidinediones with potency comparable to rosiglitazone. In atherosclerosis studies, Azelaoyl PAF promotes the uptake of oxidized low-density lipoprotein (oxLDL) by macrophages by upregulating CD36 expression. In fibroblasts from Friedreich's ataxia (FRDA) patients, Azelaoyl PAF significantly increased mRNA and protein levels of ferritin. |
Alias | 1-Hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine |
Molecular Weight | 651.85 |
Formula | C33H66NO9P |
Cas No. | 354583-69-0 |
Smiles | [C@@H](COP(OCC[N+](C)(C)C)(=O)[O-])(OC(CCCCCCCC(O)=O)=O)COCCCCCCCCCCCCCCCC |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||
Solubility Information | Ethanol: 10.00 mg/mL (15.34 mM), Sonication is recommended. PBS (pH 7.2): 6.00 mg/mL (9.20 mM), Sonication is recommended. DMSO: 6.00 mg/mL (9.20 mM), Sonication is recommended. DMF: 20.00 mg/mL (30.68 mM), Sonication is recommended. | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
PBS (pH 7.2)/DMSO/Ethanol/DMF
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.